Clinical Application of Tigecycline in a Hospital Under the Policy of National-Centralized Drug Procurement
Objective To promote the rational drug use in clinical practice and the implementation of the policy of national-centralized drug procurement(NCDP).Methods The data on the clinical use of tigecycline in a hospital before(from December 2021 to May 2022,86 cases)and after the implementation of NCDP policy(from December 2022 to May 2023,76 cases)were retrospectively analyzed,and a comprehensive evaluation was conducted from rationality,effectiveness,safety and economy.Results Before and after the implementation of NCDP policy,the main departments using tigecycline were intensive care medicine,hematology and geriatrics departments,the specimens for examination were mainly sputum and bronchoalveolar lavage fluid;the drug utilization index(DUI)of tigecycline was 1.45 and 1.63 respectively;six cases(7.41%)and seven cases(9.21%)of tigecycline-related adverse reactions were reported respectively.After the implementation of NCDP policy,the overall defined daily doses(DDDs)of tigecycline showed a decreasing trend;the rationality score of clinical use of tigecycline increased from(90.58±13.21)points to(93.12±11.35)points,the proportion of tigecycline combined with other antimicrobial drugs significantly increased(P<0.05);the clinical effective rate of tigecycline in patients increased from 88.37%to 89.47%(P>0.05);the unit price of tigecycline decreased significantly from CNY 430 to CNY 28.2,and the defined daily cost(DDC)decreased significantly from CNY 915 to CNY 51.96,with a decrease of 93.44%and 94.32%,respectively;and the costs of tigecycline and antimicrobial drugs,the proportion of tigecycline costs to antimicrobial drug costs,and the proportion of tigecycline costs to total drug costs significantly decreased(P<0.05).Conclusion After the implementation of NCDP policy,the effective rate and safety of tigecycline are similar to those before the implementation,and the economic burden of patients and medical insurance have decreased.However,tigecyclin combined with other antimicrobial drugs should be paid attention to in clinical practice.
tigecyclinenational-centralized drug procurementrationalitysafetyeffectivenesseconomy
万方数据
维普
